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Summary Effective radioimmunotherapy is limited by slow antibody clearance from the circulation, which
results in low tumour to blood ratios and restricts the dose of radiolabelled anti-tumour antibody that can be
safely administered. Avidin and streptavidin clearing agents have been shown to effectively complex and clear
radioactive biotinylated antibodies from the circulation, but their immunogenicity may limit their repeated use.
We have investigated whether polyethylene glycol (PEG) modification can reduce the immunogenicity of our
galactosylated streptavidin (gal-streptavidin) clearing agent without altering its effectiveness as a clearing agent.
The immune response evoked in mice after intraperitoneal injection of 30 ,g of gal-streptavidin was decreased
after PEG modification, as shown by lower antibody titres and a reduction in the number of mice that elicited
an anti-gal-streptavidin response. The effect of PEG-modified gal-streptavidin on the blood clearance and
tumour localisation of a "5I-labelled biotinylated anti-CEA was investigated in the LS174T human colon
carcinoma xenograft in nude mice. Although PEG modified gal-streptavidin bound the ['25I]biotinylated
antibody in vivo, effective clearance from the circulation was inhibited, resulting in very little reduction in the
levels of circulating radioactivity, together with a decrease in the antibody localised to the tumour.
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Avidin and streptavidin have frequently been used in various
clearance and pretargeting strategies with a view to increasing
the low tumour to blood ratios usually observed with
radioimmunotargeting of tumours. Both avidin and strepta-
vidin are efficient clearing agents for radiolabelled biotiny-
lated antibodies, reducing the amount of radioantibody that
normally persists in the circulation (Sinitsyn et al., 1989;
Paganelli et al., 1990a). This results in significantly higher
tumour to blood ratios (Marshall et al., 1994), which are
essential to reduce the risk of myelotoxicity while still
allowing effective radioimmunotherapy. The streptavidin-
biotinylated antibody complexes are cleared via the
reticuloendothelial system, although persistent radioactivity
in the spleen has been noted (Marshall et al., 1994). A
galactosylated form of streptavidin has recently been shown
to direct clearance of the complexes to the asialoglycoprotein
receptor of the liver, thus avoiding the accumulation of
damaging radiation in the spleen (Marshall et al., 1995).
Pretargeting strategies using streptavidin or avidin either
as the carrier of the radioisotope to a tumour pretargeted
with biotinylated antibody (Paganelli et al., 1992; Khawli et
al., 1993; Saga et al., 1994) or as the clearing agent for
biotinylated antibodies before administration of the radio-
isotope in three-step pretargeting (Paganelli et al., 1990b,
1991a) have also been described as successfully reducing the
blood background levels of radioactivity.
These avidin-biotin strategies are now moving forward
into the clinic where the immunogenicity of avidin and
streptavidin has been noted (Paganelli, 1991a,b, 1992) and
which may limit their use in repeated therapy. The
immunogenicity of murine monoclonal antibodies has been
a constant hindrance to antibody-directed therapy of
tumours, causing hypersensitivity reactions and also acceler-
ated clearance of the antibody from the circulation, rendering
the therapeutic antibody ineffective. The production of anti-
mouse antibodies can be controlled to some extent by
immunosuppressive drugs, for example Cyclosporin A
(Ledermann et al., 1988), although general immunosuppres-
sion of patients is undesirable. To overcome the problem of
immunogenicity of murine antibodies, chimeric antibodies
constructed from the variable regions of the mouse antibody
together with human constant regions have been produced
and have shown reduced immunogenicity in man (LoBuglio
et al., 1989), as have humanised antibodies constructed from
only the hypervariable complementarity-determining regions
(CDRs) of the mouse antibody built into the framework of a
human antibody (Hale et al., 1988; Hird et al., 1991).
For proteins that cannot be substituted with a human
equivalent, the problem of immunogenicity can be tackled by
polyethylene glycol (PEG) conjugation. PEG has been
covalently linked to many different proteins, after which an
increased half-life and a reduction in immunogenicity has
been reported (Abuchowski et al., 1977; Lee and Sehon,
1977; Kamisaki et al., 1981; Katre, 1990), although often
with a concomitant reduction in the activity of the proteins
(Kamisaki et al., 1981; Kitamura et al., 1991; Tsutsumi et al.,
1995).
In this paper we describe an investigation into whether the
conjugation of PEG to our galactosylated streptavidin (gal-
streptavidin) clearing agent would reduce its immunogenicity,
while still allowing effective clearance of an anti-tumour
antibody. Immunocompetent mice were immunised with gal-
streptavidin conjugated with different amounts of PEG and
their serum was tested for anti-gal-streptavidin antibodies.
The effect of PEG modification on the ability of gal-
streptavidin to complex and clear ['25I]biotinylated A5B7, a
murine monoclonal anti-CEA antibody, was investigated in
nude mice bearing the LS174T human colon carcinoma
xenograft.
Materials and methods
Preparation of PEG gal-streptavidin
Galactose conjugation Streptavidin was galactosylated as
previously described (Marshall et al., 1995). Briefly, 0.1 M
cyanomethyl -2,3,4,6 - tetra-O-acetyl- 1-thio-, -D-galactopyra-
noside in dry methanol was mixed with 10% of 0.1 M sodium
methoxide and allowed to stand for 48 h. Approximately
5.6 ml of this galactopyranoside solution was evaporated to
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dryness in a round-bottomed flask, to which 37 mg of
streptavidin (10 mg ml-' in 25 mm sodium borate, pH 8.5)
was added. After 2 h the galactosylated streptavidin was then
purified by gel filtration on Sephadex G25 (Pharmacia,
Uppsala, Sweden) and carbohydrate content assayed by the
phenol-sulphuric acid method of Dubois et al. (1956), using
a galactose standard. The streptavidin was found to contain
54 pg of galactose per mg of streptavidin.
Polyethylene glycol conjugation PEG was conjugated to gal-
streptavidin using PEG-maleimide by the method of Pedley et
al. (1994). To make the maleimide derivative, 10 mM
methoxypolyoxyethylene amine (approximate mol.wt. =
5000, Sigma, Poole, UK) was dissolved in 0.1 M sodium
phosphate, pH 7.0 and incubated with 1.2 M excess of
200 mM 3-maleimidopropionic acid N-hydroxysuccinimide
ester (Sigma) dissolved in N,N-dimethylformamide (Fluka,
Gillingham, UK) for 30 min at room temperature. An
aliquot of the reaction mixture was spotted onto a thin-
layer chromatography plate, developed with ninhydrin
(Fisons, Loughborough, UK) and the reaction was con-
sidered complete when no purple coloration could be detected
(i.e. no amine groups remained). The mixture was then
applied to a Sephadex G25 column (Pharmacia), and the
PEG-maleimide was eluted with deionised water, lyophilised
and stored in a desiccator at 4°C until used.
The PEG-maleimide reacts with thiol groups that were
incorporated into gal-streptavidin by the method of Turner et
al. (1994). The gal-streptavidin was first dialysed into 0.1 M
sodium hydrogen carbonate, pH 8.0, containing 2 mM
EDTA. A 10- or 20-fold molar excess of 2-iminothiolane
(Traut's reagent, Pierce and Warriner, Chester, UK) was
added and the reaction mixture incubated for 1 h at 37°C.
After gel filtration on Sephadex G25 to remove unreacted
Traut's reagent the average number of thiols per molecule of
streptavidin was determined by titration with 4,4'-dithiodi-
pyridine (Sigma) (Lyons et al., 1990). PEG-maleimide was
added to the thiolated gal-streptavidin at a five times molar
excess over the thiols and incubated for 1 h at 37°C. Any
unreacted PEG-maleimide was removed by gel filtration on
Sephadex G25, the number of thiol groups remaining was
assessed and therefore the number of PEG molecules
successfully conjugated could be determined. Gal-streptavi-
din with an average of 2.5 or 5 molecules of PEG per gal-
streptavidin molecule resulted, which were finally dialysed
into phosphate-buffered saline (PBS), pH 7.4. The protein
concentration of the PEG-modified gal-streptavidin was
calculated from the absorbance at 280 nm and is a measure
of the protein component of the molecule only, as PEG does
not absorb at 280 nm. To assess the apparent molecular
weight of PEG gal-streptavidin the protein was radiolabelled
with 125I by the Iodo-gen method (Fraker and Speck, 1978)
for 20 min (to a specific activity of 1 pCi pg-') and then
applied to a 110 cm x 1 cm Sephacryl S300 gel filtration
column (Pharmacia). Fractions (1.3 ml) were collected and
counted for 1251 in a multiwell gamma counter (1470 Wizard,
Wallac). Markers for the void volume, 669 kDa and 200 kDa
were also applied to the column.
ELISA to test biotin binding in vitro
Biotin binding of PEG-modified gal-streptavidin was checked
using an enzyme linked immunosorbent assay (ELISA)
system. To microtitre wells coated with CEA (2 pg ml-'),
and blocked with 3% bovine serum albumin (BSA) in PBS,
lOO1 p of biotinylated A5B7 was added at 10 pg ml-', for 1 h
at room temperature. After three washes with PBS/0.05%
Tween 20 (BDH, Poole, UK) and four washes with water,
dilutions of gal-streptavidin or PEG gal-streptavidin were
added and incubated for 30 min at room temperature. After
washing with PBS/Tween (three times) and water (four
times), 100 p1 biotin-peroxidase (diluted 1:500, Vectastain
kit, Vector Laboratories, Peterborough, UK) was added for
30 min at room temperature and the assay was then
developed with o-phenylenediamine dihydrochloride (Sig-
ma), blocked with 4M HCl and the optical density (OD) at
490 nm read on a 96-well plate reader (microplate
autoreader, Boots-Celltech Diagnostics Limited).
Immunogenicity studies
The effect of PEG conjugation on the immunogenicity ofgal-
streptavidin was tested in TO mice. Groups offour mice were
injected intraperitoneally with 30 pg of gal-streptavidin or
30 jug of PEG gal-streptavidin on days 0 and 14. All mice
were bled before treatment and on days 7, 14, 21 and 28 after
injection, and the serum of individual mice was tested for
anti-gal-streptavidin reactivity by ELISA on gal-streptavidin-
coated plates.
ELISA to testfor antibodies to gal-streptavidin
Microtitre wells were coated with gal-streptavidin at
5 jug ml-' in 0.05 M carbonate buffer, pH 9.6 for 1 h and
blocked with 3% BSA in PBS. Dilutions of mouse serum,
from 1:100, and of a mouse monoclonal anti-streptavidin
antibody standard (Monosan, Am Uden, The Netherlands)
were added to the wells for 1 h, washed with PBS/Tween and
water, and finally a 1:3000 dilution of peroxidase-linked
sheep anti-mouse Ig (Amersham, Little Chalfont, UK) was
added. The wells were washed and the assay was then
developed with o-phenylenediamine dihydrochloride, blocked
with 4M HCI and the OD at 490 nm read. Anti-gal-
streptavidin reactivity in each of the sera was related to the
antibody titre of the control anti-streptavidin antibody
standard for each assay to take into account any variation
in absorbance readings between assays which would occur if
the reaction was not stopped at exactly the same time each
time the assay was carried out. Therefore, positive anti-gal-
streptavidin response was calculated as a percentage of the
control anti-streptavidin monoclonal antibody as follows:
( titre of serum giving an OD reading of 0.3 x 100
titre of control antibody giving an OD reading of 0.3J
An absorbance value of 0.3 was chosen because this fell
within the linear range of the assay and generally included
low positive antibody reactions.
Antibody preparation
The antibody used in biodistribution studies was a murine
monoclonal anti-CEA antibody, A5B7, which has previously
been shown to localise to the human colon carcinoma
xenograft LS174T (Pedley et al., 1987). Biotinylation was
carried out by adding caproylamidobiotin-NHS ester (Sigma)
in dimethylsulphoxide (BDH) to A5B7 (1 mg ml-' in 0.1 M
sodium bicarbonate, pH 8.5) at a 24:1 molar ratio. After
incubation at room temperature for 4 h the antibody was
dialysed against PBS. The resulting biotinylated A5B7 had 10
biotins per antibody molecule as assessed by the 4'-
hydroxyazobenzene-2-carboxylic acid (HABA) dye assay
(Pierce and Warriner) (Green, 1965). lodination was carried
out using the lodo-gen method for 20 min to a specific
activity of approximately 1 mCi mg-' protein and 94% of
the ['25I]biotinylated A5B7 was found to bind CEA after
labelling when tested by affinity chromatography on a CEA-
Sepharose column. When A5B7 was iodinated to the same
specificity, 98% of the labelled antibody was found to bind to
the CEA-Sepharose column. Previous studies have shown no
significant difference in the biodistribution and tumour
localisation, to the LS174T xenograft, of ['25I]A5B7 before
and after biotinylation (Marshall et al., 1994), while in
immunohistochemical studies on acetone-fixed cryostat or
formalin-fixed paraffin sections of human tissues, biotinylated
A5B7 gave an identical pattern of reactivity to the non-
biotinylated A5B7 (data not shown).In vivo biodistribution
TO nude mice bearing the human colon carcinoma xenograft
LS174T, established by subcutaneous passaging of the cell
line LS174T (Tom et al., 1976), were injected via the tail vein
with approximately 10 ,ug 101Ci- ' [125I]biotinylated antibody.
Twenty-four hours after antibody injection test animals
received an intraperitoneal injection of either 30 pig of gal-
streptavidin or 30 ,ug PEG gal-streptavidin. Test animals were
sacrificed and blood and tissues taken to be counted for
radioactivity 1, 24 and 48 h after injection of gal-streptavidin
or PEG gal-streptavidin (25, 48 and 72 h after antibody
injection). Control animals, without administration of any
clearing agent, were sacrificed at the same time points. The
biodistribution data was calculated as percentage injected
dose per gram of tissue (% ID/g) and are mean values of
three or four mice per time point. In order to determine the
size of circulating radioactive complexes in the mice, serum
samples (taken 24 and 48 h after injection of the clearing
agents) were applied to a 110 cm x 1 cm Sephacryl S300 gel
filtration column and 1.3 ml fractions counted for 1251
radioactivity in a multiwell gamma-counter.
Results
Preparation of PEG-modified gal-streptavidin
Figure 1 shows the effect of PEG modification on the
apparent molecular weight of gal-streptavidin as assessed by
gel filtration on a Sephacryl S300 column. 5 PEG gal-
streptavidin, with a higher apparent molecular weight than
unmodified gal-streptavidin, eluted earliest with a peak at
fraction number 37 (48.1 ml), 2.5 PEG gal-streptavidin eluted
slightly later with a peak at fraction 40 (52 ml), whereas gal-
streptavidin had a peak at fraction number 46 (59.8 ml). The
void volume of the column was found to be 37.7 ml (as
assessed by the elution of blue dextran at fraction 29). The
broad elution peaks of the PEG-modified gal-streptavidin
samples indicated that different sized molecules were present
in each preparation. This was to be expected, as the PEG
reagent is comprised of different molecular weight molecules
(average mol.wt. =5000) and 2.5 PEG and 5 PEG refers only
to an average number of PEG molecules conjugated to gal-
streptavidin. If the apex of the peak is used to calculate the
average molecular weight of the protein, then values of
approximately 188 000 and 326 000 are obtained for 2.5 PEG
and 5 PEG gal-streptavidin respectively, which are higher
than the expected molecular weight of the proteins. This is
thought to be due to the random coil structure of the PEG,
which produces a much larger increase in the hydrodynamic
radius of the protein than expected from the molecular mass
alone (Delgado et al., 1992).
In vitro biotin binding of gal-streptavidin was impaired
after PEG modification as shown by ELISA (Figure 2).
However, this assay also indicates that the PEG-modified gal-
streptavidin must still have at least two functional biotin-
binding sites, since it was sandwiched between biotinylated
antibody bound to the CEA wells and the biotin peroxidase
used in the final stage of the assay.
Immunogenicity studies
The effect of PEG modification on the immunogenicity of
gal-streptavidin is shown in Figure 3. The anti-gal\
streptavidin response in each mouse is expressed as a
percentage of a positive control antibody standard. Figure
3a shows gal-streptavidin to be immunogenic in mice, with
mice eliciting an anti-gal-streptavidin response in the range of
1.0-2.1% of the control 14 days after the primary injection,
increasing to 7.5-91.7% and 24.4-156% of the control 7
and 14 days after the boost injection of gal-streptavidin (21
and 28 days after primary injection). Mice injected with 2.5
PEG gal-streptavidin (Figure 3b) showed a range in anti-gal-
streptavidin response of 0-7.2% of the control antibody 14
days after primary immunisation, and although the anti-gal-
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streptavidin antibody titres increased after the boost
injection, this was only to a maximum of 10.0% of the
control antibody 21 days after primary injection (the
remaining three mice had an anti-gal-streptavidin response
of less than 5.0%), and to a maximum of 33.8% of the
control antibody 28 days post primary injection (with the
remaining three mice showing an anti-gal-streptavidin
response of less than 11.0% of the control antibody).
Increasing the degree of modification to 5 PEG molecules
per gal-streptavidin dramatically reduced its immunogenicity
in mice, with only two of the four mice showing very low
levels of anti-gal-streptavidin antibodies after the two
injections of 5 PEG gal-streptavidin (Figure 3c). Of these
mice, one had an antibody titre of only 1.8% of the control
antibody, 28 days after primary injection, and one mouse had
a response that was lower than the usual limits of the assay,
but was estimated to be less than 0.5% of the control
antibody. The remaining two mice, in which no anti-gal-
streptavidin response was detected, were injected 1 week later
with unmodified gal-streptavidin, followed by a boost
injection of gal-streptavidin 2 weeks later. No anti-gal-
streptavidin response was detected, up to 28 days after the
primary gal-streptavidin injection (14 days after the boost
injection).
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Figure 1 Effect of PEG modification on the apparent molecular
weight of gal-streptavidin as assessed by gel filtration on
Sephacryl S300. *, gal-streptavidin; 0, 2.5 PEG gal-streptavi-
din; fC, 5 PEG gal-streptavidin. Markers for the void volume,
669kDa and 200kDa were also applied to the column.
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Figure 2 Effect of PEG modification on the biotin binding of
gal-streptavidin (*), 2.5 PEG gal-streptavidin (0) and 5 PEG
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Effect of PEG modification on gal-streptavidin clearance of
biotinylated A5B7
2.5 PEG-modified gal-streptavidin When 2.5 PEG gal-
streptavidin was administered 24 h after injection of
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Figure 3 Anti-gal-streptavidin response in individual mice after
injection of gal-streptavidin or PEG-modified gal-streptavidin.
Mice were injected with 30pg of (a) gal-streptavidin, (b) 2.5 PEG
gal-streptavidin or (c) 5 PEG gal-streptavidin on days 0 and 14,
bled on days 7, 14, 21 and 28 and sera tested for anti-gal-
streptavidin antibodies by ELISA. Results are expressed as a
percentage of the anti-streptavidin control antibody.
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Figure 4 Biodistribution of [125I]biotinylated A5B7 (a) h, (b)
24h and (c) 48h after injection of gal-streptavidin (L) or 2.5
PEG gal-streptavidin (M) clearing agents. Test animals were
injected with the clearing agent 24h after antibody injection and
compared with animals injected with [125I]biotinylated A5B7
alone (_). Vertical bars indicate s.d.
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Figure 5 Biodistribution of [125ljbiotinylated A5B7 (a) 1 h, (b)
24h and (c) 48h after injection of gal-streptavidin (L) or 5
PEG gal-streptavidin (M) clearing agents. Test animals were
injected with the clearing agent 24h after antibody injection and
compared with animals injected with [1251]biotinylated A5B7
alone (_). Vertical bars indicate s.d.
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gal-streptavidin clearing agent resulted, as expected, in a
rapid decrease in blood radioactivity from 13.6% ID/g to
3.6% ID/g, with the gal-streptavidin-biotinylated antibody
complexes being cleared through the liver.
Twenty-four hours after administration of 2.5 PEG gal-
streptavidin (Figure 4b) the level ofradioactivity in the blood
was again similar to the control animals without any clearing
agent. By this time point though, a reduction in tumour
radioactivity from 24.4% ID/g to 14.3% ID/g was observed,
thus resulting in a tumour to blood ratio of only 2.0+0.13.
The effect of administration of unmodified gal-streptavidin
on the biodistribution of ['251I]biotinylated A5B7 is shown in
comparison, and although a reduction in antibody localised
at the tumour was also observed (from 24.4% ID/g to
12.5% ID/g), the increased blood clearance to only 0.8% ID/
g resulted in an improved tumour to blood ratio of 16.7+5.3.
Figure 4c shows that by 48 h after injection of 2.5 PEG
gal-streptavidin a reduction in blood radioactivity was noted
(from 7.6% ID/g to 2.4% ID/g), although this was not as
great as that seen after administration of the unmodified gal-
streptavidin (0.28% ID/g). A similar decrease in tumour
radioactivity was also observed after administration of 2.5
PEG gal-streptavidin, therefore resulting in no improvement
in the tumour to blood ratio (2.5+ 1.2 compared with
3.8+2.2 in control animals without administration of
clearing agent), whereas the unmodified gal-streptavidin
gave an improved tumour to blood ratio of 29.7+14.4
(range 16.9 to 48.8).
5 PEG-modified gal-streptavidin 5 PEG gal-streptavidin had
no effect on the biodistribution of ['25I]biotinylated A5B7 1 h
after administration, whereas unmodified gal-streptavidin
reduced the level of circulating ['251]biotinylated A5B7 3.3-
fold from 15.5% ID/g in the controls to 4.7% ID/g (Figure
Sa).
By 24 hours there was still little difference between the
radioactivity levels in the circulation of control animals and
those injected with S PEG gal-streptavidin clearing agent
(Figure 5b), but tumour levels of the latter were reduced by
half to 16.6% ID/g, resulting in a poor tumour to blood ratio
of 1.5+0.8 compared with 2.5+ 1.0 in antibody alone control
animals. Clearance with unmodified gal-streptavidin gave a
corresponding tumour to blood ratio of 29.6+23.5 (range
from 9.9 to 63.2).
A similar pattern was again seen 48 h after administration
of the clearing agents (Figure 5c), with a further reduction in
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Figure 6 Analysis of serum by gel filtration on Sephacryl S300
24h after administration of 2.5 PEG gal-streptavidin (0) or 48h
after administration of 5 PEG gal-streptavidin (-) (PEG gal-
streptavidin was administered 24h after [125I]biotinylated A5B7
injection). [1251]biotinylated A5B7 control was also applied to the
column (*).
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tumour activity after injection of 5 PEG gal-streptavidin (to
9.1% ID/g), resulting in a tumour to blood ratio of only
1.4 +0.2 compared with 3.1 + 1.5 for the antibody alone
control animals and 48.1 + 16.1 (range from 33.6 to 68.6)
after clearance with unmodified gal-streptavidin. The blood
clearance 24 and 48 h after injection of the unmodified gal-
streptavidin was even greater than the corresponding groups
previously presented in Figure 4, resulting in higher tumour
to blood ratios. The reason for this further improvement in
gal-streptavidin clearance in this series of data is not known.
Gelfiltration analysis of serum
In order to ascertain whether the 125I radioactivity remaining
in the blood 24 and 48 h after administration of 2.5 or 5
PEG gal-streptavidin was circulating as free ['25I]biotinylated
A5B7 or as a PEG gal-streptavidin-biotinylated antibody
complex, mouse serum samples were applied to a Sephacryl
S300 gel filtration column. Figure 6 shows that the 1251
radioactivity in the serum was eluted as a high molecular
weight complex, at fraction 29 (equivalent to the void
volume), with no free ['25I]biotinylated A5B7 being detect-
able.
Discussion
Radioimmunotherapy is often limited by the persistence of
radiolabelled antibody in the circulation, which causes bone
marrow toxicity and limits the dose of radioactivity that can
be safely administered to the patient. Various strategies to
circumvent myelotoxicity have included using second anti-
body clearing agents to complex and clear the first, anti-
tumour antibody (Begent et al., 1982; Sharkey et al., 1988;
Pedley et al., 1989), and extracorporeal immunoadsorption
using either an anti-mouse column to reduce the level of
circulating murine antibody (Lear et al., 1991) or an avidin
column to reduce the blood background levels ofbiotinylated
antibodies (Norrgren et al., 1993). Extracorporeal immu-
noadsorption has an advantage over other clearance systems
of not causing accumulation of antibody complexes in the
liver and spleen. Also Press et al. (1993) have reported
impressive responses to high-dose radioimmunotherapy of B-
cell lymphoma, with myelotoxic side-effects being minimised
with autologous bone marrow support.
Other clearing and pretargeting strategies which have been
investigated for reducing the dose of radioactivity to the
blood involve the use of avidin or streptavidin which, being
of non-human origin, invoke an immune response in humans.
In one study 7/12 patients were reported by Paganelli et al.
(1991a) to have developed anti-avidin antibodies after
injection of 5 mg of avidin. Antibody therapy has frequently
been hampered by the immunogenicity of murine monoclonal
antibodies, although less immunogenic humanised antibodies
are now becoming more widely available for clinical use.
There is great interest in the development of a clearing agent
that is also non-immunogenic and therefore an investigation
to reduce the immunogenicity of our gal-streptavidin clearing
agent (Marshall et al., 1995) was undertaken.
Polyethylene glycol (PEG) is a linear, water-soluble,
uncharged, flexible polymer that is available in various
molecular weights and can be readily conjugated to
proteins. PEG conjugation has been reported to abolish or
reduce the immunogenicity of many proteins and was
therefore an ideal candidate in an attempt to reduce the
immunogenicity of our gal-streptavidin clearing agent.
The conjugation of PEG to gal-streptavidin was found to
decrease its immunogenicity in mice (Figure 3). Anti-gal-
streptavidin antibody titres after injection of 2.5 PEG gal-
streptavidin were lower than those ofcontrol animals injected
with unmodified gal-streptavidin. When the degree of PEG
modification was increased to 5 PEG molecules per gal-
streptavidin, only two out of four mice elicited an immune
response, and in these mice the response was not only
weaker, but was also later after primary injection of the
protein. These findings are similar to those of Katre (1990)
who noted that only three out of ten rabbits mounted an
immune response to PEG-IL2, compared with ten out of ten
immunised with unmodified interleukin 2 (IL-2), and did so
later than those injected with IL-2. It was also noted that an
increase in the degree of PEG modification further reduced
the immunogenicity of the IL-2 protein in mice, as found
with our PEG gal-streptavidin.
It has been reported that tolerance can be induced in mice
after immunisation with PEG-conjugated proteins, depending
on the degree of PEG modification and dose of PEG protein
(Savoca et al., 1984). Wilkinson et al. (1987a) found an
approximately 80% reduction in the antibody response to
human IgG if PEG-human IgG had been injected 6-43 days
before, and it has also been reported that induced tolerance
can be transferred to naive mice by T cells and T cell extracts
(Wilkinson et al., 1987b). It may be possible to induce
tolerance to gal-streptavidin with PEG gal-streptavidin, as
indicated by the two mice that failed to show any immune
response to gal-streptavidin after prior injection of 5 PEG
gal-streptavidin, although a full investigation with more
animals is needed to confirm this finding.
Loss in bioactivity after PEG modification has been
frequently noted for many proteins. Although increasing
the number of PEG molecules per gal-streptavidin also
reduced the immunogenicity, this increase in PEG
conjugation also resulted in a significant decrease in biotin
binding of the gal-streptavidin when tested by ELISA
(Figure 2). Increasing the degree of PEG modification has
been reported by others to result in a decrease in the
bioactivity of the protein (Wieder et al., 1979; Kitamura et
al., 1991; Tsutsumi et al., 1995) and although early PEG
modification methods were particularly harsh, protein
inactivation has been reduced by using different conjuga-
tion methods (Abuchowski et al., 1984). Several reasons for
the reduction in bioactivity after PEG modification have
been proposed, including conjugation of PEG to residues
that are vital for the reactivity of the protein (Wieder et
al., 1979; Veronese, 1994). This is unlikely to be the reason
for the loss in biotin binding after PEG conjugation to gal-
streptavidin, as the PEG was linked via lysine residues that
are not considered to be involved in the biotin binding
process of streptavidin (Wilchek and Bayer, 1989). PEG
modification is not thought to cause gross conformational
changes as circular dichroism and nuclear magnetic
resonance (NMR) spectroscopic studies by Suzuki et al.
(1984) and Banci et al. (1990) did not show any significant
differences between unmodified and PEG-modified proteins.
It has been suggested that the decrease in bioactivity after
PEG conjugation is due to interference with substrate
approach to the active site. Yoshinaga et al. (1987) found
that alkaline phosphatase conjugated with low molecular
weight PEG had greater activity than when modified to the
same degree of lysine substitution but with higher
molecular weight PEG, indicating that the long chain of
the polymer itself sterically hinders the substrate from
binding to the active site.
Both forms of PEG gal-streptavidin were tested to assess
whether their ability to complex and clear [125I]biotinylated
antibodies from the circulation had been altered. One hour
after gal-streptavidin injection neither the 2.5 nor the 5 PEG
gal-streptavidin had reduced the circulating radioactivity,
whereas unmodified gal-streptavidin had reduced the blood
radioactivity by approximately 3-fold. It has been suggested
that PEG-modified proteins are slower in their diffusion from
a subcutaneous injection site than unmodified proteins
(Dreborg and Akerblom, 1990) and therefore the lack of
blood clearance at this early time point was initially thought
to be due to PEG gal-streptavidin taking longer to gain
access to the blood stream from the peritoneal cavity.
The results obtained 24 h after PEG gal-streptavidin were
rather surprising in that, although blood radioactivity levels
were similar to the control animals without clearing agent,
the tumour levels were reduced significantly (1.7-fold and 2-
fold reduction after 2.5 and 5 PEG gal-streptavidinPEG modification of a gal-streptavidin clearing agent
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respectively). A similar finding was observed 48 h after
administration of the 5 PEG molecule and, although blood
radioactivity levels after injection of the 2.5 PEG gal-
streptavidin were less than the control animals with
['25I]biotinylated A5B7 alone, the low levels of radioactivity
in the tumour resulted in a tumour to blood ratio of only
2.5+ 1.2 compared with a tumour to blood ratio of
29.7+14.4 after administration of unmodified gal-streptavi-
din. The gel filtration of the serum at these later time points
after PEG gal-streptavidin administration (Figure 6) indi-
cated that the activity in the blood was circulating as a high
molecular weight complex. Therefore, although the biotin
binding of PEG gal-streptavidin was inhibited in vitro, the
PEG modified gal-streptavidin was still able to bind to the
[1251]biotinylated A5B7 in vivo sufficiently to form large
radiolabelled complexes (as shown by the shift in the peak
of radioactivity from fraction 42, as expected for
[1251I]biotinylated A5B7, to elution in the void volume of the
column). PEG modified proteins are known to have an
extended half-life in vivo (Kamisaki et al., 1981; Tsutsumi et
al., 1995) irrespective of whether the usual pattern of
clearance is via the reticuloendothelial system, is receptor-
mediated carbohydrate recognition, or passive excretion
(Beauchamp et al., 1983). PEG is thought to act as a shield
around the protein that protects it from elimination from the
body, making clearance slower without changing the route of
clearance, as shown by competition experiments of Beau-
champ et al. (1983). Therefore, it appears that even though
the ['251]biotinylated antibody was part of a high molecular
weight complex that would normally be cleared rapidly from
the body via asialoglycoprotein receptors in the liver, the
PEG component of the PEG gal-streptavidin-bound
[1251]biotinylated antibody prevented its rapid removal from
the circulation, presumably by masking receptor recognition.
The radioactivity at the tumour site is thought to be
maintained at a high level if the blood levels of the
radiolabelled antibody are also high, due to the existence of
an equilibrium between bound and non-bound, circulating
antibody. Therefore, rapid removal of circulating antibody
after administration of a clearing agent disrupts this
equilibrium, resulting in reduced levels of antibody asso-
ciated with the tumour (Sharkey et al., 1988,1992). In this
present study, it appears that the radiolabelled antibody was
present in the circulation only as part of a high molecular
weight complex, not as free [1251I]biotinylated antibody.
Therefore, the antibody would be inhibited from binding at
the tumour site. Any equilibrium between tumour-bound and
circulating antibody would be disrupted and any antibody
that dissociated from the tumour or was shed with the
tumour antigen would not be replenished, therefore, although
radioactivity was still elevated in the circulation after PEG
gal-streptavidin, the high levels of radioactivity at the tumour
site could not be maintained.
In conclusion, while the immunogenicity of a streptavidin
clearing agent can be successfully reduced by conjugation
with PEG, this advantage is compromised by the slow
clearance of the subsequent PEG gal-streptavidin-biotiny-
lated antibody complexes, which results in very limited
reduction in the level of damaging radioactivity circulating
in the blood, while also reducing tumour accumulation. PEG
modification is very appealing for many non-human proteins
used in the clinic, but the use of PEG for decreased
immunogenicity of an antibody clearing agent is clearly
limited. Preliminary data suggests that PEG gal-streptavidin
could make the mice tolerant to the unmodified clearing
agent. PEG proteins have previously been implicated as
tolerogens in mice and, although this is an attractive use for
PEG-modified gal-streptavidin, the ability of PEG-modified
proteins to induce tolerance in man is yet to be tested. The
gal-streptavidin used in this series of experiments had
relatively low amounts of galactose compared with previous
gal-streptavidin clearing agents that have been used. It may
be possible that ifthe degree ofgalactosylation was increased,
then faster clearance via the asialoglycoprotein receptor may
still be possible even after PEG conjugation and this is under
investigation.
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